Moderna’s shares were up nearly 3% at the time of writing. The vaccine was previously available for pediatric populations ...

With the 2025 influenza season starting earlier than usual, the NICD urges South Africans to stay vigilant against seasonal ...

House Democrats on the Oversight Committee are calling for an urgent briefing with staff from the Centers for Disease Control ...

The University of Texas and Austin Public Health created a measles simulator for school districts and private schools around ...

Fungi are increasingly resistant to antifungals, and the variation in resistance has significantly increased. This is evident ...

The WHO warns that a new, more dominant COVID strain is on the loose—and spreading rapidly. What to know about the XFG ...

A coalition of doctors’ groups and public health organizations sued the U.S. government on Monday over the decision to stop ...

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

Pediatricians say the parents of their patients are anxious and confused about vaccine safety and access as federal ...

The new results helped boost Moderna’s stock by more than 4% in early trading June 30, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

Inside one of those nondescript rooms last week, the Advisory Committee on Immunization Practices (ACIP), an independent panel that makes vaccine recommendations to the Centers for Disease Control and ...